Blog

We at KYMOS and ASPHALION are long-time partners in providing analytical and regulatory services to international pharma and biotech sectors. Our testimony goes beyond the conventional “CRO trading with UK clients” to overcome internalization barriers. Our respective services are part of a complex international supply chain that makes the effects of Brexit more visible and quantifiable. Quality Control (QC) is one of the most interdisciplinary departments at KYMOS with high demand from international clients, particularly for EU Batch Testing and Release for drug products and IMPs.

The awards ceremony was held during the CataloniaBio & HealthTech Gala, shared via live streaming.

Judit Anido, president of CataloniaBio & HealthTech: “We need more success stories like Kymos. One of the biggest challenges we are facing as a sector is to consolidate the business sphere”

Now more than ever, immunology is a hot topic as we face the numerous challenges of the COVID19 pandemic. The world is patiently awaiting new therapies and vaccines to combat this disease in hopes of returning some sense of normalcy to our lives. 

KYMOS’ immunology expert, Dr. Carles Morte, shares his outlook on the future of promising new gene- and cell-based therapies and monoclonal antibodies developed against viral and other diseases. We talk to him about the technical evaluation required as the therapeutic target turns to the ever-so-complex immune system. 

Introduction

Our quality control manager and co-founder of Pharmaprogress, Dr Luca Gramaccioni has nearly two decades of experience in mass spectrometry. Here, he talks about the latest Nitrosamine deadline extension and our ahead-of-the-curve screenings.